1. Home
  2. |Insights
  3. |DC Insurance Commissioner Clarifies Charitable Obligations of Blue Cross/Blue Shield Plan

DC Insurance Commissioner Clarifies Charitable Obligations of Blue Cross/Blue Shield Plan

Client Alert | 1 min read | 05.17.05

On May 15, 2005, Commissioner Mirel of the District of Columbia Department of Insurance, Securities and Banking (“DISB” or the “Department”) issued a report addressing controversy about alleged charitable obligations of Group Hospitalization and Medical Services, Inc. (“GHMSI”), the Blue Cross Blue Shield plan for the Washington, D.C. area. The report followed a DISB hearing in March into whether, and to what extent, GHMSI was obligated by its federal charter to engage in charitable activities. The DISB inquiry was initiated after a community advocacy organization alleged that GHMSI had a legal obligation to fund community health projects and other charitable causes and to extend such benefits to the public beyond its policyholders.

DISB's report concluded that GHMSI's Congressional charter, issued in 1939, declared it a charitable organization with a primary legal obligation and mission of providing health insurance to its policyholders. The Department also found that GHMSI's charter provides it with the authority to engage in additional activities, beyond the provision of health insurance, to support the health of the communities in the greater Washington area. Commissioner Mirel found that GHMSI has a “social responsibility that goes beyond its legal obligations” and that the Company is in appropriate financial condition to take additional steps to support public health.

The Commissioner's report does not state how much charitable activity GHMSI should conduct. It does emphasize, however, that consistent with GHMSI's obligations to its policyholders, the Company must maintain a significant surplus. DISB declined to make a finding as to what should be the maximum level of surplus for GHMSI, noting that it is the responsibility of GHMSI's Board to determine an appropriate amount.

Contacts

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...